News|Articles|April 17, 2026

AACE Annual Meeting 2026 Preview: 7 Trials to Know

View slated expert interviews and 7 clinical trials to watch at AACE Annual Meeting 2026.

The American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 kicks off in Las Vegas, Nevada, on Wednesday, April 22, 2026. As the global burden of obesity, diabetes, dyslipidemia, and other related conditions continues to rise, this year's conference is set to explore the latest evidence-based strategies, clinical innovations, and interdisciplinary approaches that position nutrition as both a therapeutic tool and a foundation for lifelong health.

Related to this article

Adrian Dan, MD | Image Credit: Summa Health

October 16th, 2026

Revita Reduces Weight Regain After GLP-1 Discontinuation in REMAIN-1

A single Revita procedure preserved about 80% of tirzepatide-induced weight loss at six months in the REMAIN-1 pivotal cohort.

October 18th, 2026

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

Plasma and exhaled breath sphingolipid signatures differed between IPF and fibrotic hypersensitivity pneumonitis.

October 18th, 2026

ASPEN: Sputum Color Associated With Bronchiectasis Disease Activity

A post hoc analysis linked more purulent patient-reported sputum to higher neutrophil elastase activity and greater bronchiectasis disease activity.

October 18th, 2026

Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD

In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.

October 18th, 2026

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

Chronic proton pump inhibitor use carried 60% greater odds of asthma exacerbation and nearly 4-fold odds of rescue corticosteroid use in a matched cohort of 2456 patients.

October 16th, 2026

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

George Washko, MD, discusses a late-breaking OBERON/TITANIA analysis showing tozorakimab reduces segmental mucus plug scores in COPD.

October 16th, 2026

Diabetes Dialogue: Twiist AID Data and the New ADA/EASD Type 2 Algorithm

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss a major breakthrough with the Twiist insulin pump and the recent ADA/EASD T2D guidelines.

October 16th, 2026

Elafibranor Lowers ALP in PBC Patients Switching From Obeticholic Acid

Real-world data from ACG 2026 show elafibranor lowered ALP in patients with PBC who switched from obeticholic acid and in those new to second-line therapy.